Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The idiotype–anti-idiotype antibody network is a complex regulatory system within the adaptive immune system, originally proposed by Niels Jerne (Jerne, 1974, Ann. Immunol.). It posits that the variable regions (idiotypes) of antibodies and B-cell receptors are themselves recognized as antigens by other antibodies (anti-idiotypes), creating a self-regulating web that maintains immune homeostasis and self-tolerance (Shoenfeld, 2004, Cleve. Clin. J. Med.). In healthy individuals, this network helps suppress the expansion of autoreactive B-cell clones and regulates the magnitude of immune responses to foreign antigens (Lemke, 2014, Encycl. Med. Immunol.). Dysregulation of this network is implicated in the development of autoimmune diseases, where the balance between pathogenic autoantibodies and protective anti-idiotypes is lost. Therapeutically, this system is exploited through the use of intravenous immunoglobulin (IVIG), which contains a diverse array of anti-idiotypic antibodies that can neutralize pathogenic autoantibodies (Kazatchkine & Dietrich, 1993, Clin. Exp. Immunol.). Furthermore, idiotype vaccines are used in the treatment of B-cell lymphomas to induce a specific immune response against the unique idiotypes expressed on the surface of malignant B cells. The study of B-cell and autoantibody repertoires within this network provides insights into the mechanisms of immune memory and the transition from health to chronic inflammatory disease.
Modulation of immune homeostasis through the binding of anti-idiotypic antibodies to the variable regions (idiotypes) of pathogenic autoantibodies or B-cell receptors, leading to neutralization of the antibodies or suppression of the corresponding B-cell clones (Kazatchkine & Dietrich, 1993, Clin. Exp. Immunol.).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Idiotype–anti-idiotype antibody network.